CN1269509C - Medicine for treating chronic nephritis, and its prepn. method - Google Patents
Medicine for treating chronic nephritis, and its prepn. method Download PDFInfo
- Publication number
- CN1269509C CN1269509C CN 200410006353 CN200410006353A CN1269509C CN 1269509 C CN1269509 C CN 1269509C CN 200410006353 CN200410006353 CN 200410006353 CN 200410006353 A CN200410006353 A CN 200410006353A CN 1269509 C CN1269509 C CN 1269509C
- Authority
- CN
- China
- Prior art keywords
- medicine
- filtrate
- weight portion
- weight portions
- relative density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 206010018367 Glomerulonephritis chronic Diseases 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims description 16
- 238000000034 method Methods 0.000 title abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- 241000222640 Polyporus Species 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 241000208340 Araliaceae Species 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- -1 drying Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 208000004880 Polyuria Diseases 0.000 abstract description 7
- 102000009027 Albumins Human genes 0.000 abstract description 6
- 108010088751 Albumins Proteins 0.000 abstract description 6
- 230000035619 diuresis Effects 0.000 abstract description 6
- 210000000952 spleen Anatomy 0.000 abstract description 6
- 230000003907 kidney function Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 244000233890 Alisma plantago Species 0.000 abstract 1
- 235000017300 Alisma plantago Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 description 13
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 10
- 201000008383 nephritis Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 102000007562 Serum Albumin Human genes 0.000 description 7
- 108010071390 Serum Albumin Proteins 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 241001251068 Formica fusca Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses a medicine for treating chronic nephritis, which is prepared from ginseng, white atractylodes rhizome, baical skullcap root, tuckahoe, water plantain, bupleurum root, polyporus and cassia twig. The medicine for treating chronic nephritis has the effects of strengthening the spleen, nourishing the stomach, clearing away the heat, promoting the diuresis, expelling the wind and dissipating the evil, and can be used for treating the chronic nephritis. The clinical symptoms can be reduced, the urinary protein can be obviously reduced, the albumin can be obviously increased, the renal function is improved and protected, and no side or toxic effect exists. The present invention also discloses a method for preparing the medicine.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of chronic nephritis, specifically, is that a kind of to contain by Chinese crude drug be the medicine that feedstock production becomes effective ingredient.The invention still further relates to the preparation method of this medicine.
Background technology
Chronic nephritis full name chronic glomerulonephritis is caused by multiple reason, is primary in the immune inflammation disease of glomerule, is the intractable persistent ailment that present modern medicine circle is generally acknowledged.Existing document has also been reported the Chinese medicine of some treatment nephritis, discloses the Yichanmanshenkang medicine for curing nephroses of oral administration for treating chronicity nephritis as CN 1268355A, and this medicine is to be made by insect medicines such as Formica fusca, Eupolyphaga Seu Steleophagas, but curative effect and imprecise; CN 1088442A discloses a kind of medicine for the treatment of nephritis, and it is to be made by Radix Ginseng, Ramulus Cinnamomi, Radix Bupleuri etc., but same curative effect is also imprecise.So present still Chinese medicine of the treatment nephritis of a kind of determined curative effect of demand.The inventor has accumulated secular clinical experience, thinks that the pathogenic characteristic of chronic nephritis is a deficiency in origin and excess in superficiality, and deficiency in origin mainly shows as in various degree deficient, wherein important and common with spleen kidney qi Yin bivacuity of internal organs such as lung, spleen, liver, kidney.Mark is real mainly to be by due to many risk factors and the pathological product, as ailment said due to cold or exposure, damp and hot, blood stasis and turbid damp etc., wherein connects with damp and hot stream and had the greatest impact by ailment said due to cold or exposure repeatedly.Based on above understanding, in conjunction with clinical application experience for many years, having founded with nourishing spleen and kidney, clearing away heat-damp and promoting diuresis, the diffusing heresy of dispeling the wind is rule treatment chronic nephritis.Select the Chinese crude drug prescription to be prepared into medicine with this rule,, thereby finished the present invention through pharmacology and clinical experiment checking determined curative effect.
Summary of the invention
Goal of the invention of the present invention provides a kind of medicine for the treatment of chronic nephritis.
Another object of the present invention provides the preparation method of this medicine.
Medicine of the present invention is made up of effective ingredient or effective ingredient and acceptable accessories, wherein prepares raw materials of effective components and is: Radix Ginseng, the Rhizoma Atractylodis Macrocephalae, Radix Scutellariae, Poria, Rhizoma Alismatis, Radix Bupleuri, Polyporus and Ramulus Cinnamomi.
Radix Ginseng, the strong Pi QI invigorating of the Rhizoma Atractylodis Macrocephalae; Radix Scutellariae, Polyporus, Poria, Rhizoma Alismatis clearing away heat-damp and promoting diuresis; Radix Bupleuri, Ramulus Cinnamomi dispel the wind and remove heresy; Modern medicine study shows that Radix Ginseng, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus have the adjustment immunologic function, and renal function protecting reduces effects such as urine protein; Heat-clearing and diuresis-promoting drug such as Radix Scutellariae, Rhizoma Alismatis can be removed immune complex in the blood, suppresses antigen antibody reaction, renal function protecting; The medical instrument that dispels the wind such as Radix Bupleuri, Ramulus Cinnamomi has tangible antiallergic, antiallergic action effect.All medicines share has spleen invigorating taste stomach, clearing away heat-damp and promoting diuresis, the evil effect of loosing of dispeling the wind, and is used for the treatment of chronic nephritis, can improve clinical symptoms, can reduce urine protein significantly again, and raising albumin improves and renal function protecting.
In order to obtain better therapeutic, the consumption of raw material is:
Radix Ginseng 10-15 weight portion, Rhizoma Atractylodis Macrocephalae 10-15 weight portion, Radix Scutellariae 5-10 weight portion, Poria 25-30 weight portion, Rhizoma Alismatis 5-10 weight portion, Radix Bupleuri 10-15 weight portion, Polyporus 10-15 weight portion, Ramulus Cinnamomi 5-10 weight portion.
In order to obtain best curative effect, the consumption of raw material is:
Radix Ginseng 10 weight portions, the Rhizoma Atractylodis Macrocephalae 12 weight portions, Radix Scutellariae 9 weight portions, Poria 30 weight portions, Rhizoma Alismatis 10 weight portions, Radix Bupleuri 15 weight portions, Polyporus 15 weight portions, Ramulus Cinnamomi 9 weight portions.
The preparation method of effective ingredient can adopt the routine fashion of pharmaceutical field, as decoction and alcohol sedimentation technique or ethanol extract from water precipitation, and perhaps convection drying, pulverize.
Preferred manufacturing procedure is: take by weighing raw material, Radix Ginseng is decocted with water 2-3 time, each 0.5-1.5 hour, collecting decoction filtered, and filtrate is left standstill; All the other medicines decoct with water 2-3 time, and each 0.5-1.5 hour, merge decoction, filter, filtrate is left standstill; Merge above-mentioned filtrate, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, room temperature to be chilled to adds ethanol and makes precipitation, gets supernatant concentration to relative density 60-65 ℃ of survey 1.20, add water, stir, leave standstill, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40 as effective ingredient.
Preferred preparation method is: take by weighing raw material, Radix Ginseng is decocted with water twice, each 1.5 hours, collecting decoction filtered, and filtrate is left standstill; All the other medicines decoct with water twice, and each 1.5 hours, merge decoction, filter, filtrate is left standstill; Merge above-mentioned filtrate, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, room temperature to be chilled to adds equivalent ethanol and makes precipitation, gets supernatant concentration to relative density 60-65 ℃ of survey 1.20, add 1 times of amount of water, stir, left standstill 8 hours, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40 as effective ingredient.
Medicine of the present invention can be with above-mentioned effective ingredient convection drying, and pulverize is made powder; Perhaps above-mentioned effective ingredient and pharmaceutically acceptable conventional adjuvant are made various dosage forms, preferred electuary, granule, oral liquid, tablet or capsule.1 part of the thick paste of effective ingredient is preferably got in the preparation of granule, and with 3 parts of sucrose, 1.25 parts in dextrin and ethanol are made granule, drying, granulate, packing.
Medicine of the present invention has spleen invigorating taste stomach, clearing away heat-damp and promoting diuresis, the evil effect of loosing of dispeling the wind, and can be used for treating chronic nephritis, can improve clinical symptoms, can reduce urine protein significantly again, and raising albumin improves and renal function protecting, and without any side effects.
Embodiment 1:
1) takes by weighing following raw materials according: Radix Ginseng 10g, Rhizoma Atractylodis Macrocephalae 12g, Radix Scutellariae 9g, Poria 30g, Rhizoma Alismatis 10g, Radix Bupleuri 15g, Polyporus 15g, Ramulus Cinnamomi 9g;
2) Radix Ginseng is decocted with water twice, each 1.5 hours, collecting decoction filtered, and filtrate is left standstill;
3) all the other medicines decoct with water twice, and each 1.5 hours, merge decoction, filter, filtrate is left standstill; Merge above-mentioned filtrate, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, room temperature to be chilled to adds equivalent ethanol and makes precipitation, gets supernatant concentration to relative density 60-65 ℃ of survey 1.20, add 1 times of amount of water, stir, left standstill 8 hours, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40;
4) get 1 part of thick paste, with 3 parts of sucrose, 1.25 parts in dextrin and ethanol are made granule, drying, granulate, packing.
Embodiment 2:
Take by weighing following raw materials according: Radix Ginseng 10g, Rhizoma Atractylodis Macrocephalae 10g, Radix Scutellariae 5g, Poria 25g, Rhizoma Alismatis 5g, Radix Bupleuri 10g, Polyporus 10g, Ramulus Cinnamomi 5g; All the other are identical with embodiment 1.
Embodiment 3:
Take by weighing following raw materials according: Radix Ginseng 15g, Rhizoma Atractylodis Macrocephalae 15g, Radix Scutellariae 10g, Poria 30g, Rhizoma Alismatis 10g, Radix Bupleuri 15g, Polyporus 15g, Ramulus Cinnamomi 10g; All the other are identical with embodiment 1.
Test example 1: medicine of the present invention is to the effect viewing test of mice basement membrane nephritis
One, material and method:
1. material:
Animal: large ear rabbit, male, 2-2.5Kg, the Beijing Medical University animal center provides; BALB/C mice, female, 18-22g, institute of biological products, Beijing animal center provides.
Medicine: A medicine: LIUWEI DIHUANG WAN prescription, decocting boil half an hour 2 times, and get filtrate and be concentrated into desired concn, 1/2,1,3 times of dose,equivalents, refrigerator is preserved.The medicament composing prescription of B medicine: embodiment 1, decocting boil half an hour 2 times, and get filtrate and be concentrated into desired concn, 1/2,1,3 times of dose,equivalents, refrigerator is preserved.Rabbit igg: U.S. Miles company product.
2. method: the method that adopts rabbit igg accelerating type mice anti-basement membrane nephritis
2.1. nephrolytic sera preparation
With the Emulsion immunize rabbit that contains mice glomerular basement membrane and Freund's complete adjuvant, 1 time weekly, totally 6 times, getting rabbit anteserum is nephrolytic sera.
2.2. glomerulonephritis is made film and administration
Mice elder generation lumbar injection rabbit igg, the intravenous injection nephrolytic sera is made film again, evenly is divided into 5 groups according to the mouse retention protein level after 5 days.Carry out two batches of tests altogether.First test divides 5 groups: model group: A medicine 17.4g/Kg (dose,equivalent), 52.2g/Kg; B medicine 14.1g/Kg (dose,equivalent), 42.3g/Kg.Every group 14.Second batch of test: model group: A medicine 8.7g/Kg (dose,equivalent), 17.4g/Kg; B medicine 7.0g/Kg (dose,equivalent), 14.1g/Kg.Every group 13.15 on model.In 3 weeks of continuous oral administration, survey urine protein weekly, plasma albumin and blood urea nitrogen.
Two, result:
First sees Table 1-3; Second batch sees Table 4-6.
First experimental model nephritis is heavier, and most of mices are with ascites, and model group to 21 day is recovered (blood urea nitrogen 10.4mmol/L) not yet, and mortality rate is higher, is 35.7%.The equivalence of A medicine and 3 times of dose,equivalents do not improve plasma urea nitrogen, though some the time have and reduce urine protein trend (the 21st day) and rising plasma albumin (equivalent agent flow control 14 days), but animal dead is too many, and analysis may not counted interior relevant with person's of being in a bad way death.Mortality rate is higher during 3 times of dose,equivalents, reaches 71.4%.The B medicine does not obviously improve plasma urea nitrogen and albumin yet, and mortality rate is 28.6% a little less than model group, from treatment 12 days, can obviously reduce urine protein; No significant difference between equivalence and 3 times of dose,equivalents.Nephrolytic sera dosage is adjusted in second batch of experiment, and model is lighter slightly than first, only occurs ascites, mortality rate 6.7% individually.1/2 equivalence of A medicine and dose,equivalent still can not improve plasma urea nitrogen, and the urine protein fall is little, only the 1/2 dose,equivalent plasma albumin that can raise, the B medicine does not improve blood urea nitrogen, but the plasma albumin that can raise, treated for 2 weeks after, can obviously reduce urine protein, 1/2 dose,equivalent is slightly poor.
Three, brief summary
1.A being the mice anti-basement membrane nephritis, 1/2,1 and 3 times of dose,equivalent of medicine shows clear and definite therapeutical effect, 1 and 3 times of dose,equivalent mortality rate height, and whether poisonous waiting studied.
2.B 1/2,1 and 3 times of dose,equivalent of medicine has certain therapeutical effect to the mice anti-basement membrane nephritis, can obviously reduce urine protein and rising plasma albumin, the effect of its treatment nephritis may mainly realize by diuresis.
The variation of protein content in table 1 urine (X ± SD)
| Group | Dosage (g/Kg) | Urine protein (mg/dl) | |||||
| Before the medicine | Administration 6 days | Administration 9 days | Administration 12 days | Administration 18 days | Administration 21 days | ||
| Model | 400±164 (14) | 380±1 53(13) | 290±2 1.1 (10) | 295±15 .8(10) | 275±35. 4(10) | 272±26.4 (9) | |
| The A medicine | 17.4 | 375±149 (14) | 315±1 03(11) | 275±2 6.4 (10) | 257±73 .2(7) | 242±73. 6(6) | 203±78 (6) |
| The A medicine | 52.2 | 400±164 (14) | 359±1 44(8) | 286±2 4.4(7) | 267±40 .8(6) | 238±94. 6(4) | 213±75 (4) |
| The B medicine | 14.1 | 375±149 (14) | 300±0 (12) | 275±2 6.1 (12) | 264±32 .3(11) * | 225±54 (10) * | 230±35 (10) * |
| The B medicine | 42.3 | 400±164 (14) | 300±0 (13) | 273±2 6.1 (11) | 265±33 .7(10) * | 230±25. 8(10) ** | 190±56.8 (10) ** |
Annotate: the t test:
*P＜0.05,
*P＜0.01.
The variation of table 2 plasma urea nitrogen (X ± SD)
| Group | Dosage (g/Kg) | Blood urea nitrogen (mmol/L) | ||
| Administration 7 days | Administration 14 days | Administration 21 days | ||
| Model | 22.3±9.4(12) | 11.6±5.6(10) | 10.4±4.6(9) | |
| The A medicine | 17.4 | 23.4±6.9(12) | 9.7±3.9(7) | 8.3±4.7(6) |
| The A medicine | 52.2 | 22.5±10.3(9) | 7.5±1.5(5) | 6.9±0.9(4) |
| The B medicine | 14.1 | 17.7±5.3(12) | 9.8±3.4(10) | 8.5±2.4(10) |
| The B medicine | 42.3 | 26.6±7.4(12) | 11.7±5.2(10) | 10.3±4.0(10) |
Annotate: the t test:
*P＜0.05,
*P＜0.01.
The variation of table 3 plasma albumin (X ± SD)
| Group | Dosage (g/Kg) | Albumin (g/L) | ||
| Administration 7 days | Administration 14 days | Administration 21 days | ||
| Model | 23.0±1.5(12) | 26.3±2.1(10) | 29.0±2.6(9) | |
| The A medicine | 17.4 | 24.1±3.6(12) | 30.2±2.1(7) ** | 30.5±1.1(6) |
| The A medicine | 52.2 | 23.2±2.4(9) | 23.8±3.4(5) | 26.0±1.7(4) ** |
| The B medicine | 14.1 | 24.4±2.6(12) | 26.8±3.6(10) | 27.4±2.5(10) |
| The B medicine | 42.3 | 25.7±3.6(12) ** | 28.3±2.4(10) | 30.1±1.7(10) |
Annotate: the t test:
*P＜0.05,
*P＜0.01.
The variation of protein content in table 4 urine (X ± SD)
| Group | Dosage (g/Kg) | Urine protein (mg/dl) | |||
| Before the medicine | Administration 7 days | Administration 14 days | Administration 21 days | ||
| Model | 340±128 (15) | 340±128 (15) | 304±113(14) | 249±78(14) | |
| The A medicine | 8.7 | 354±131 (13) | 323±99 (13) | 245±44(10) | 220±35(10) |
| The A medicine | 17.4 | 346±138 (13) | 323±99 (13) | 232±51(11) | 209±66(11) |
| The B medicine | 7.0 | 354±131 (13) | 296±14 (13) | 221±58(12) ** | 204±50(12) |
| The B medicine | 14.1 | 345±138 (13) | 296±14 (13) | 225±54(12) ** | 188±38(12) * |
Annotate: the t test:
*P＜0.05,
*P＜0.01.
The variation of table 5 plasma urea nitrogen (X ± SD)
| Group | Dosage (g/Kg) | Blood urea nitrogen (mmol/L) | ||
| Administration 7 days | Administration 14 days | Administration 21 days | ||
| Model | 21.1±15.5(15) | 10.1±4.3(14) | 8.2±1.7(14) | |
| The A medicine | 8.7 | 23.4±10.6(13) | 12.2±4.6(10) | 9.5±2.4(10) |
| The A medicine | 17.4 | 18.6±8.3(13) | 8.5±1.7(11) | 8.0±2.6(11) |
| The B medicine | 7.0 | 20.9±11.2(13) | 11.1±5.7(12) | 8.0±2.1(11) |
| The B medicine | 14.1 | 19.2±8.0(13) | 9.9±3.0(12) | 8.2±1.5(12) |
Annotate: the t test:
*P＜0.05,
*P＜0.01.
The variation of table 6 plasma albumin (X ± SD)
| Group | Dosage (g/Kg) | Albumin (g/L) | ||
| Administration 7 days | Administration 14 days | Administration 21 days | ||
| Model | 24.5±3.5(15) | 28.4±4.6(14) | 27.3±1.6(14) | |
| The A medicine | 8.7 | 25.1±3.1(13) | 32.2±3.6(10) * | 30.5±2.9(10) ** |
| The A medicine | 17.4 | 26.2±3.2(13) | 26.8±3.5(11) | 28.6±3.7(4) |
| The B medicine | 7.0 | 26.5±3.2(13) | 31.5±4.1(12) | 29.8±2.9(10) * |
| The B medicine | 14.1 | 25.7±2.8(13) | 31.8±2.2(12) * | 29.2±2.4(10) * |
Annotate: the t test:
*P＜0.05,
*P＜0.01.
Claims (6)
1, a kind of medicine for the treatment of chronic nephritis, it is characterized in that it is made up of effective ingredient or effective ingredient and acceptable accessories, wherein prepare raw materials of effective components and be: Radix Ginseng 15-10 weight portion, Rhizoma Atractylodis Macrocephalae 10-15 weight portion, Radix Scutellariae 5-10 weight portion, Poria 25-30 weight portion, Rhizoma Alismatis 5-10 weight portion, Radix Bupleuri 10-15 weight portion, Polyporus 10-15 weight portion, Ramulus Cinnamomi 5-10 weight portion.
2, according to the described medicine of claim 1, wherein prepare the raw materials of effective components consumption and be: Radix Ginseng 10 weight portions, the Rhizoma Atractylodis Macrocephalae 12 weight portions, Radix Scutellariae 9 weight portions, Poria 30 weight portions, Rhizoma Alismatis 10 weight portions, Radix Bupleuri 15 weight portions, Polyporus 15 weight portions, Ramulus Cinnamomi 9 weight portions.
3, according to claim 1 or 2 described medicines, its Chinese medicine is electuary, granule, oral liquid, tablet or capsule.
4, according to the preparation method of any one described medicine in claim 1 or 2, it comprises and takes by weighing raw material, and Radix Ginseng is decocted with water 2-3 time, and each 0.5-1.5 hour, collecting decoction filtered, and filtrate is left standstill; All the other medicines decoct with water 2-3 time, and each 0.5-1.5 hour, merge decoction, filter, filtrate is left standstill; Merge above-mentioned filtrate, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, and room temperature to be chilled to adds equivalent ethanol and makes precipitation, get supernatant concentration to relative density 60-65 ℃ of survey 1.20, add water, stir, leave standstill, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40 as effective ingredient, again thick paste is made electuary, granule, oral liquid, tablet or capsule.
5, according to the preparation method of the described medicine of claim 4, it comprises and takes by weighing raw material, and Radix Ginseng is decocted with water twice, and each 1.5 hours, collecting decoction filtered, and filtrate is left standstill; All the other medicines decoct with water twice, and each 1.5 hours, merge decoction, filter, filtrate is left standstill; Merge above-mentioned filtrate, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, and room temperature to be chilled to adds equivalent ethanol and makes precipitation, get supernatant concentration to relative density 60-65 ℃ of survey 1.20, add 1 times of amount of water, stir, leave standstill, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40, again thick paste is made electuary, granule, oral liquid, tablet or capsule.
6, according to the preparation method of the described medicine of claim 5, wherein will be as 1 part of the thick paste of effective ingredient, with 3 parts of sucrose, 1.25 parts in dextrin and ethanol are made granule, drying, granulate, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410006353 CN1269509C (en) | 2004-02-27 | 2004-02-27 | Medicine for treating chronic nephritis, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410006353 CN1269509C (en) | 2004-02-27 | 2004-02-27 | Medicine for treating chronic nephritis, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1559467A CN1559467A (en) | 2005-01-05 |
| CN1269509C true CN1269509C (en) | 2006-08-16 |
Family
ID=34439760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410006353 Expired - Lifetime CN1269509C (en) | 2004-02-27 | 2004-02-27 | Medicine for treating chronic nephritis, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1269509C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623332B (en) * | 2013-12-10 | 2015-07-22 | 王正椋 | Traditional Chinese medicine for treating perinephritis |
-
2004
- 2004-02-27 CN CN 200410006353 patent/CN1269509C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1559467A (en) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1839944A (en) | Granular composition for reducing blood fat and process for producing the same | |
| CN1201782C (en) | Medicine composition for treating mammary gland proliferation, and its prepn. method | |
| CN1269509C (en) | Medicine for treating chronic nephritis, and its prepn. method | |
| CN1965951A (en) | Blood tonic capsule having ass hide and method for preparing same | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN1270750C (en) | Medicine for treating chronic nephritis, and its prepn. method | |
| CN101543574B (en) | Chinese medicinal composition for treating pulmonary interstitial fibrosis | |
| CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN1298366C (en) | Medicine composition for treating essential hypotension | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1108159C (en) | Traditional Chinese medicine for curing diabetes and kidney deficiency | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN1723956A (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN1876044A (en) | A Chinese medicinal composition for treating infant fever caused by exogenous pathogen and preparation method thereof | |
| CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN1274338C (en) | Traditional Chinese medicine for treating aplastic anemia and its preparation process | |
| CN113876919B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, pharmaceutical preparation and application thereof | |
| CN1475261A (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN1128634C (en) | Hepatitis B recuperating medicine granule | |
| CN1036503C (en) | Medicine for treating systemic lupus erythematosus and producing method thereof | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. | |
| CN1834108B (en) | Acanthopanax giraldii Harms compound polysaccharide, preparation technique, uses and its compound polysaccharide composition | |
| CN1823945A (en) | Chinese medicinal preparation for treating fatly liver and its preparation method | |
| CN1785410A (en) | Preparation method of ready prepared chinese medicinal granules for treathing pains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: ZHUHAI ANSHENG FENGHUANG PHARMACEUTICAL Co.,Ltd. Assignor: Li Guocheng Contract fulfillment period: 2007.1.1 to 2012.1.1 Contract record no.: 2009440001629 Denomination of invention: Medicine for treating chronic nephritis and its preparing process Granted publication date: 20060816 License type: Exclusive license Record date: 20091021 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.1.1 TO 2012.1.1; CHANGE OF CONTRACT Name of requester: ZHUHAI ANSHENG FENGHUANG PHARMACY CO., LTD. Effective date: 20091021 |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060816 |
|
| CX01 | Expiry of patent term |